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Aim: To study an intensity of prooxidant processes and activity of antioxidant enzymes in tumor tissue of two Lewis lung carci-
noma variants (LLC and LLC/R9) differing by their proliferative, metastatic, and angiogenic potential (LLC/R9 as compared 
to LLC is characterized by lower metastatic activity, higher proliferative and angiogenic potential). Materials and Methods: The 
in vitro study was carried out using cultured LLC and LLC/R9 cell lines, and in vivo on 50 female С57/BL6 mice. The indexes 
of prooxidant processes and activity of antioxidant enzymes have been studied using the methods of experimental oncology, optical 
spectroscopy, fluorescent spectroscopy, electron paramagnetic resonance, statistical analysis. Results: There has been determined 
the coherence of results on 1.5 fold higher (p < 0.01) level of spontaneous generation of reactive oxygen species (ROS) by LLC 
cells in vitro compared to LLC/R9 cells, and twice (p < 0.05) higher content of secondary products of lipid peroxidation at 14th and 
17th day of tumor growth in LLC compared to that in LLC/R9. It has been shown that deficiency of nutrient substrates determines 
an increase (p < 0.01) of ROS production in LLC/R9 cells what is in congruence with the data on accumulation of nitrosyl com-
plexes of heme iron in mitochondria of LLC/R9 during tumor growth. Activity of superoxide dismutase during tumor growth has 
altered in unmonotonous way: starting from 14th day of growth it sharply increased by 147% (17th day, LLC) and 217% (20th day, 
LLC/R9), and then decreased to the level registered at 14th day. Progressive decrease of activity of glutathione peroxidase (GP) 
and glutathione-S-transferase (GST) during LLC growth has been accompanied with the decrease of the level of reduced glutathi-
one (GSH) by 70% (p < 0.05). In the case of LLC/R9 the decrease of GP activity at initial stages of tumor growth correlated with 
significant increase of GSH level in the tumor — by 250% (p < 0.01). It has been shown that in LLC/R9 tumors (unlike to LLC), 
GSH utilization is mostly provided by GST, its significantly higher activity has been detected in LLC/R9 tumors compared 
to LLC. Conclusion: We have revealed a number of peculiarities of antioxidant system functioning in LLC and LLC/R9 tumors and 
have shown a relation between an activity of antioxidant system and some biological properties of studied tumor variants.
Key Words: Lewis lung carcinoma variants, reactive oxygen species, lipid peroxidation, antioxidant enzymes, glutathione-dependent 
enzymes.
Insufficient rate of vascularization compared with 
high proliferation rate of tumor cells (TC) results in limited 
supply of TC with oxygen and nutrients, accumulation 
of metabolic products and reactive oxygen species (ROS) 
in tumor microenvironment what could be characterized 
as a situation of metabolic stress [1]. From other side, 
hypoxic conditions promote manifestation of many ef-
fects of adaptive character directed toward TC survival, 
including suppression of apoptosis, increased glycolysis 
intensity, induction of autophagy and mitophagy, digestion 
of alternative energetic substrates, increased synthesis 
of angiogenesis factors etc [2, 3].
ROS occupy a central place in formation of adaptive 
response toward metabolic stress; their role as messen-
gers in signal pathways involved in proliferation, TC death 
via apoptosis, necrosis or autophagy, regulation of cell 
energetic, angiogenesis, migration ability, interaction with 
extracellular stroma etc, is well-known [3]. At the same 
time an excess of ROS which could be caused by dysfunc-
tion of TC mitochondria as well as persistent inflammatory 
process in tumor lesion, determines the development 
of oxidative stress, damaging effects toward biologic 
membranes, proteins, lipids, nucleic acids. Along with this 
oxidative stress could be caused by malfunction of anti-
oxidant system (AOS).
Realization of ROS effects in cell depends on AOS state 
which provides neutralization of free radical molecules and 
consists from high molecular weight enzyme components 
and low molecular weight non-enzyme components [4]. 
AOS activity determines preservation of TC viability in un-
favorable conditions. Key ROS scavengers include super-
oxide dismutase (SOD) which neutralizes superoxide-anion 
into hydrogen peroxide which in turn is utilized by catalase 
(CAT) and glutathione peroxidase (GP) [4, 5]. The results 
of studies in vitro and in vivo point on relation between 
SOD functioning in tumors and their growth characteris-
tics [6–8]. According to the data of other authors, some 
GP isoforms have membrane localization, while CAT which 
exerts neutralization of lipid peroxides, fatty acids, alkylpe-
roxides, and hydrogen peroxide in locations close to cell 
membranes [9]. Also, intracellular redox status depends 
on ratio between reduced (GSH) and oxidized (GSSG) 
forms of glutathione, what is regulated with the involve-
ment of GP, glutathione reductase (GR), and glutathione-
S-transferase (GST) [5]. GSТ uses GSH as a substrate and 
participates in neutralization of xenobiotics metabolized 
with involvement of cytochrome Р450, products generated 
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via oxidative stress, endogenous toxic compounds, etc. 
[5, 10]. There has been shown a role of AOS components 
(in particular, Mn-SOD, peroxy- and thioredoxines, CAT) 
as proteins — tumor suppressors [6–8].
Evaluation of the state of AOS enzymes in TC dif-
fering by their biological patterns, could be informative 
for determination of the ways of TC adaptation to the de-
ficiency of oxygen and nutrient substrates and also for 
identification of targets for possible influence on the state 
of oxidative processes in TC for induction of metabolic ca-
tastrophe, achievement of anticancer and antimetastatic 
effects. That’s why this work was aimed on the study of in-
tensity of prooxidant processes and activity of antioxidant 
enzymes in two Lewis lung carcinoma variants — LLC and 
LLC/R9 which differ by growth kinetics, intensity of metas-
tasis, ability to autophagy, sensitivity to the action of inhibi-
tors of tumor angiogenesis, and to deficiency of energetic 
substrates [11–14]. In particular, LLC/R9 as compared 
to LLC is characterized by lower metastatic acti vity, higher 
proliferative and angiogenic potential and significant sen-
sitivity to antiangiogenic therapy and nutrient deficiency.
MATERIALS AND METHODS
In the study there were used two variants of Lewis 
lung carcinoma (LLC and LLC/R9) kindly provided 
by National Bank of Cell Lines and Transplanted Tumors 
of R.E. Kavetsky Institute of Experimental Pathology, On-
cology and Radiobiology, National Academy of Sciences 
of Ukraine (Kyiv, Ukraine). LLC/R9 variant was generated 
from the wild-type LLC strain after 9 sequential cis-diam-
minedichloroplatinum (cis-DDP) cycles in vivo [11, 12]. 
The LLC and LLC/R9 cells were cultured in vitro in RPMI 
1640 medium (Sigma, USA) supplemented with 10% 
fetal calf serum (Sigma, USA), 2 mM L-glutamine, and 
40  μg/ ml gentamicin at 37 °C in atmosphere with 5% CO2. 
In vivo research has been performed on 50 С57/BL6 fe-
male mice 2–2.5 months old, weighing 18–23 g bred in vi-
varium of IEPOR NASU. The mice were inoculated with LLC 
and LLC/R9 cells in the thigh muscle of the right hind leg 
(1•106 cells in 0.1 ml of Hank’s solution).
The mice from 1st group (n = 25) were transplanted 
with LLC cells, the animals from 2nd group (n = 25) — with 
LLC/R9 cells. The study was approved by regional Ethics 
Committee and responded to the rules on the work with 
experimental animals.
Activities of antioxidant enzymes and LPO product 
content in tumor tissue homogenates were investigated 
during tumor growth at 14th, 17th, 20th, and 25th day after 
cancer cell inoculation (5–7 animals per each time point).
Total protein content in tumor tissue homogenates 
was determined by the method of Greenberg [15]. Total 
SOD activity was analyzed using spectrophotometry 
and measurement of nitroformazan content generated 
in reaction of superoxide-anion and nitroblue tetrazolium 
which competes with the enzyme [16]. CAT activity in the 
samples was determined according to [17] by the content 
of complex of ammonium molybdate and residual hydro-
gen peroxide. The content of thiobarbituric acid reactive 
substances (TBARS), secondary lipid peroxidation (LPO) 
products, was determined as described in [18] in the re-
action with thiobarbituric acid. GP activity was analyzed 
by the method [19], based on determination of GSSG 
accumulation. GR acti vity was evaluated according to [19] 
by the decrease of NADPH content in the reaction of GSSG 
reduction. Activity of GST was determined with the use 
of kit [19] (Sigma, USA) by measuring the rate of genera-
tion of glutathione-S-2,4-dinitrobenzene in the reaction 
of GSSG and 1-chloro-2,4- dinitrobenzene [10]. Content 
of GSH was determined according to [20] in the reaction 
with 5,5’-dithiobis-2-nitrobenzoic acid.
Functional state of TC mitochondria was analyzed 
by the level of nitrosyl complexes of heme iron (NCHI) (NO-
complexes) with gav = 2,007 according to the data of EPR 
spectra. For this purpose, from tumor and muscle tissues 
there have been prepared cylindrical samples of special 
size (d = 4.0 mm, l = 25–35 mm), which were frozen and 
stored at temperature 77 К. EPR spectra were done at tem-
perature 77 К using spectrophotometer Е-109 Varian 
(USA). Muscle tissue from left leg of each mouse served 
as an individual control. To determine initial values of EPR 
signals, intact mice (n = 5) were used.
The level of intracellular ROS in TC was determined 
with the use of 2,7-dichlorofluorescein diacetate (Sigma, 
USA) after 1-day incubation of TC in the medium with dif-
ferent content of glucose and glutamine according to [21]. 
To create the deficiency in glucose and glutamine, we have 
used glucose-free medium (Sigma, USA) and glutamine-
free medium (Sigma, USA) supplemented with 10% FBS 
(Sigma, USA) and gentamicin. Control cultures were incu-
bated in standard medium which contains 11 mM glucose 
and 2 mM glutamine, and was supplemented with FBS 
and gentamicin.
Statistical analysis of obtained results was per-
formed with the use of descriptive methods, and Stu-
dent’s t-criterion.
RESULTS
Intensity of prooxidant processes in LLC and LLC/
R9 tumors. The results of the study of ROS production 
by LLC and LLC/R9 cells in vitro indicated significantly 
higher (by 60%, p < 0.01) level of spontaneous generation 
of free radical oxygen forms in LLC cells compared to LLC/
R9 cells in the conditions of their cultivation in the medium 
with standard content of glucose and glutamine and upon 
normoxia (Fig. 1). Significant decrease of concentration 
of glucose or glutamine in culture medium did not shift 
significantly ROS level in LLC cells but caused an increase 
of ROS level in LLC/R9 cells by 26% (p < 0.01) and 76% 
(p < 0.01) respectively compared to the control.
The data on higher ROS level in LLC cells compared 
to LLC/R9 cells in vitro are in agreement with the results 
of the study of content of TBARS — secondary products 
of LPO. TBARS content in LLC tumors was by 50% higher 
than that in LLC/R9 tumors (p < 0.05), at least at 14th and 
17th day after tumor transplantation (Fig. 2). The maximal 
elevation of TBARS level in LLC tumors was recorded 
at 17th day of growth, while in LLC/R9 tumors TBARS 
content did not differ significantly during tumor growth.
The data on the content of NCHI the presence of which 
evidences on disturbance of electron-transport com-
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plexes of tumor mitochondrial respiratory chain, for both 
tumor variants in their growth dynamics are presented 
in Fig. 3 and show the different character of NCHI changes 
in the case of LLC and LLC/R9. In the case of LLC NCHI 
level remained relatively constant during tumor growth, 
while in the case of LLC/R9 the progressive increase 
of NCHI content has been recorded: by 163% (p < 0.05) 
and by 255% (p < 0.05) at 20th and 25th day respectively. 
At 25th day after tumor transplantation, the NCHI content 
in LLC/R9 tumors was by 178% higher than that in LLC 
tumors (p < 0.05).
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Fig. 1. Intracellular ROS level in LLC and LLC/R9 cells after 1 day of in-
cubation in medium with different content of glucose and glutamine. 
*Differences are significant as compared to the corresponding value 
for LLC; **for LLC/R9 cells differences are significant as compared 
to the corresponding control (p < 0.05); r.u. — relative units
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Fig. 2. The content of TBARS in tumor during LLC and LLC/
R9 growth. *Differences are significant as compared to the corre-
sponding value for LLC; **differences are significant as compared 
to the value on the 14th day of LLC growth (p < 0.05)
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Fig. 3. The level of nitrosyl complexes of heme iron in tumor during 
LLC and LLC/R9 growth. *Differences are significant as compared 
to the corresponding value for LLC; **differences are significant 
as compared to the value on the 14th day of LLC/R9 growth (p < 0.05); 
r.u. — relative units
Activities of SOD, CAT, and glutathione-dependent 
enzymes in LLC and LLC/R9 tumors. The results 
of study of the changes of SOD and CAT activities in LLC 
and LLC/R9 tumors during their growth are presented 
in Table 1. SOD activity in tumor tissue increased at the pe-
riod of intense tumor growth in both tumor variants, how-
ever, in the case of LLC maximal SOD activity has been 
registered at 17th day of tumor growth, while in the case 
of LLC/R9 — at 20th day. Nonmonotonous character 
of CAT activity changes (at least of their mean values) 
was revealed for both LLC and LLC/R9. Trend of decrease 
of this activity was registered at 17th day of tumor growth 
but due to high variability of the values observed changes 
were not statistically significant.
Table 1. SOD and CAT activity in tumor during LLC and LLC/R9 growth
Time after 
TC transplan-
tation, day
SOD, r.u./mg protein·min CAT, r.u./mg protein·min
LLC LLC/R9 LLC LLC/R9
14 27.7±5.2 22.4±5.0 42.7±15.4 21.5±5.5
17 68.2±0.96** 34.6±0.6* 15.4±1.98 11.8±5.3
20 25.9±3.4 69.9±16.0*,** 41.8±8.6 28.9±4.5
25 27.0±7.2 21.2±5.6 23.9±3.5 21.4±2.3
Note: *differences are significant as compared to the corresponding value for LLC; 
**differences are significant as compared to the value on the 14th day for each tu-
mor (p < 0.05); r.u. — relative units.
The data on activities of glutathione-dependent en-
zymes (GP, GR, GST) in LLC and LLC/R9 tumors, are 
presented in Fig. 4 and Table 2. As it’s seen in Fig. 4, 
GP activity in tumor tissue of both tumor variants has been 
decreasing monotonically. For example, in both tumor 
variants GP activity has decreased from its maximal values 
registered at 14th day of tumor growth by more that 70% 
(p < 0.05) at 20th day.
Table 2. GST and GR activity in tumor during LLC and LLC/R9 growth
Time after 
TC inocula-
tion, day
GST, μmol CDNB/
mg protein·min
GR, μmol NADPH/
mg protein·min
LLC LLC/R9 LLC LLC/R9
14 1.142±0.165 2.138±0.311* 12.95±1.50 7.30±2.90
17 0.411±0.207** 1.444±0.207* 7.42±2.72 9.99±1.15
20 0.678±0.079** 1.916±0.372* 9.51±1.02 4.40±0.98*
25 0.732±0.103 1.385±0.462 6.13±1.36** N/A
Note: *differences are significant as compared to the corresponding va lue for LLC; 
**differences are significant as compared to the value on the 14th day for each tu-
mor (p < 0.05); N/A — not available.
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Fig. 4. GP activity in tumor during LLC and LLC/R9 growth. *Diffe-
rences are significant as compared to the corresponding value for 
LLC; **differences are significant as compared to the value on the 14th 
day for each tumor (p < 0.05)
Unlike to GP, the character of changes in GST ac-
tivity during LLC growth significantly differed from that 
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of LLC/R9. As it is shown in Table 2, in the case of LLC 
GST activity in tumor homogenates has been decreasing 
significantly along with tumor growth: in particular, at 17th 
and 20th days its activity was lower by 64% (p < 0.05) and 
by 41% (p < 0.05) compared with respective index at 14th 
day. At the same time in the case of LLC/R9, GST activity 
in tumor homogenates was 2–4 fold higher (p < 0.05) 
than respective indexes in case of LLC and didn’t change 
significantly during tumor growth.
As it seen in Table 2 LLC and LLC/R9 growth was ac-
companied by the decrease of GR activity. The reduction 
of GR level by 40% (p < 0.05) was observed at 20th day 
of LLC/R9 growth. In case of LLC statistically significant 
decrease of GR activity by 53% was shown at 25th day 
as compared to that at 14th day of tumor growth.
The decrease of GP and GST activities in tumor tissue 
during LLC growth was not accompanied by expected 
increase of reduced glutathione (GSН), which is a sub-
strate for these enzymes. In contrary, at 20th and 25th days 
of LLC growth GSН content in tumor decreased by 70% 
(p < 0.05) and 62% (p < 0.05) compared to corresponding 
value at 14th day respectively (Fig. 5). 
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Fig. 5. The content of reduced glutathione (GSH) in tumor during 
LLC and LLC/R9 growth. *Differences are significant as compared 
to the corresponding value for LLC; **differences are significant 
as compared to the value on the 14th day for each tumor (p < 0.05)
In the case of LLC/R9, GSН content at 14th day of tumor 
growth was by 3.5 fold lower (p < 0.05) compared to re-
spective value in the case of LLC and increased (4 fold, p < 
0.05) up to maximal values at 17th day whereupon GSH lev-
el significantly (p < 0.05) diminished at 20th and 25th days.
DISCUSSION
Despite their identical origin and genotype, two vari-
ants of Lewis lung carcinoma — LLC and LLC/R9 signifi-
cantly differ by their biologic properties. LLC/R9, obtained 
by experimental progression of parental variant LLC 
toward formation of drug resistance to cis-DDP, is chara-
cterized by low metastatic potential and high proliferation 
potential compared to LLC [11, 12, 22]. For example, at 25th 
day of tumor growth the number of lung metastases and 
their volume in mice with transplanted LLC/R9 is nearly 
3 times lower compared to these indexes in animals with 
LLC, while the volume of primary tumors in mice with LLC/
R9 is nearly twice larger than that in LLC-bearing mice. 
LLC/R9 is cha racterized also by high (compared to LLC) 
angiogenic potential which is expressed in 1.5 times higher 
VEGF production level (as key inducer of tumor angioge-
nesis), high sensitivity to inhibitors of tumor angioge nesis 
and significant dependence of TC growth from nutrient 
substrate content.
It is known that during tumor development its mi-
croenvironment significantly alters toward an increased 
deficiency of nutrient substrates (energetic and plastic 
ones) and accumulation of metabolic products of tumor 
and normal cells (involved in tumor process) [23]. Such 
changes in TC microenvironment appear due to defi-
ciency of tumor tissue vasculature (caused by pathologic 
angiogenesis), leading to formation of metabolic stress, 
altered tumor cellular composition, and biologic patterns 
of the cells. Significant role in such changes belongs 
to prooxidant processes and peculiarities of functioning 
of antioxidant system of TC [1–3]. The results of our study 
support these observations.
The study of AOS functioning upon LLC and LLC/
R9 growth has shown that the character of alteration of ac-
tivity of some enzymes of antioxidant defense and intensity 
of prooxidant processes in tumor tissue differed between 
these tumor variants. An intensity of prooxidant processes 
was evaluated by the content of secondary LPO products, 
NCHI and ROS levels in TC. LLC, highly-metastatic variant, 
was characterized by increased content of LPO se condary 
products (at least at intense period of tumor growth) 
compared to LLC/R9, and significantly higher basal ROS 
level (mostly peroxides) in vitro compared to LLC/R9 cells 
under conditions of cell incubation in culture medium with 
standard content of glucose and glutamine.
At the same time in the case of LLC/R9 nutrient sub-
strate deficiency (which is usually observed in a growing 
tumor) led to statistically significant increase of ROS 
content, what could be possibly related to dysfunction 
of TC mitochondria and/or insufficient functioning of their 
antioxidant system. The first assumption has been sup-
ported with our data on NCHI accumulation in TC mito-
chondria and decreased content of iron-sulfur centers 
(data not shown) during LLC/R9 growth. As it is known, 
these complexes are formed via production of nitrogen 
radicals (NO) by mitochondrial NO-synthase (mNOS) 
in TC and/or inducible NO-synthase (iNOS) in macro-
phages, and are capable to modulate the rate of electron 
transport through the components of electron-transport 
chain of mitochondria and initiate cell hypoxia. In such 
conditions NO may react with superoxide-radical with 
following generation of peroxynitrite — an oxidizing 
and nitrosy lizing agent, and cause the development 
of mitochondrial dysfunction [24]. Mitochondrial dys-
function of LLC/R9 cells may also develop due to higher 
(compared to LLC) sensitivity to nutrient substrate defi-
ciency; in LLC/R9 cells which were incubated for a long 
period without replacement of culture medium and were 
deficient in nutrient substrates, there has been recorded 
an appearance of structurally defective mitochondria [13].
Some differences between LLC and LLC/R9 have been 
also found in the character of kinetics of changes in activi-
ty of antioxidant enzymes, in particular, SOD — first-line 
antioxidant defense enzyme. Despite the fact that maxi-
mal SOD value in both carcinoma variants was practically 
equal, in the case of LLC its maximal activity was achieved 
at 17th day of tumor growth while in the case of LLC/R9 — 
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only at 20th day. It should be noted that maximal level 
of SOD is observed at 17th day of LLC growth when these 
cancer cells are characterized by maximum migration 
capacity resulting in their high metastatic activity [11, 12]. 
The relation between SOD activity and metastatic potential 
of a tumor is supported by the data [25, 26]. According 
to the data of literature, an excess of H2O2, which appears 
due to increased SOD activity and decreased GP activity 
(which were observed at 17th day of LLC growth versus 
same indexes at 14th day), could determine an initiation 
of signal cascades which positively regulate migration/
metastatic activity of TC, in particular, activation of Snail, 
increase of the content of phosphorylated ERK1/2 kinase, 
activation of matrix metalloproteinase-9, cause structural 
instability of E-cadherin, etc [25]. From other side, an ex-
cess of H2O2, may also determine oxidation of polyunsatu-
rated fatty acids with generation of alkylperoxides and fatty 
acid peroxides leading to increased accumulation of LPO 
products which has been observed at 17th day of LLC 
growth compared to that at 14th day.
The functioning of glutathione-dependent system 
during LLC growth also differed from that in LLC/R9, in par-
ticular by the character of changes in GSH content and 
GST activity. Really, the obtained data evidence on the fact 
that in LLC/R9 tumors GSH utilization is mostly directed 
on support of functional activity of GST as an enzyme 
which has a higher affinity to substrate; the level of GST ac-
tivity was significantly higher in LLC/R9 tumors compared 
to LLC. Usually, glutathione level and activity of enzymes 
of glutathione-dependent system in drug-resistant malig-
nant cells are increased [27, 28]. It could not be excluded 
that significantly higher level of GST activity, peculiarities 
of alterations in GSH content in LLC/R9 during tumor 
growth and low ROS level in LLC/R9 cells could be related 
to drug resistance as far as LLC/R9 variant was generated 
by multistage experimental progression of the wild-type 
LLC strain toward formation of the resistance to cis-DDP.
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